Stefan Carlsson1, Fredrik Jäderling2, Anna Wallerstedt1, Tommy Nyberg3, Johan Stranne4, Thordis Thorsteinsdottir5, Sigrid V Carlsson6, Anders Bjartell7, Jonas Hugosson4, Eva Haglind8, Gunnar Steineck3,9. 1. Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institutet, Stockholm, Sweden. 2. Department of Molecular Medicine and Surgery, Section of Radiology, Karolinska Institutet, Stockholm, Sweden. 3. Department of Oncology and Pathology, Division of Clinical Cancer Epidemiology, Karolinska Institutet, Stockholm, Sweden. 4. Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 5. Faculty of Nursing, School of Health Sciences, University of Iceland, Iceland, Sweden. 6. Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Urology, Skåne University Hospital, Lund University, Lund, Sweden. 8. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 9. Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Abstract
OBJECTIVES: To analyse oncological and functional outcomes 12 months after treatment of very-low-risk prostate cancer with radical prostatectomy in men who could have been candidates for active surveillance. PATIENTS AND METHODS: We conducted a prospective study of all men with very-low-risk prostate cancer who underwent radical prostatectomy at one of 14 participating centres. Validated patient questionnaires were collected at baseline and after 12 months by independent healthcare researchers. Biochemical recurrence (BCR) was defined as prostate-specific antigen (PSA) ≥0.25 ng/mL or treatment with salvage radiotherapy or with hormones. Urinary continence was defined as <1 pad changed per 24 h. Erectile function was defined as ability to achieve erection hard enough for penetration more than half of the time after sexual stimulation. Changes in tumour grade and stage were obtained from pathology reports. We report descriptive frequencies and proportions of men who had each outcome in various subgroups. Fisher's exact test was used to assess differences between the age groups. RESULTS: Of the 4003 men in the LAPPRO cohort, 338 men fulfilled the preoperative national criteria for very-low-risk prostate cancer. Adverse pathology outcomes included upgrading, defined as pT3 or postoperative Gleason sum ≥7, which was present in 35% of the men (115/333) and positive surgical margins, which were present in 16% of the men (54/329). Only 2.1% of the men (7/329) had a PSA concentration >0.1 ng/mL 6-12 weeks postoperatively. Erectile function and urinary continence were observed in 44% (98/222) and 84% of the men (264/315), respectively, 12 months postoperatively. The proportion of men achieving the trifecta, defined as preoperative potent and continent men who remained potent and continent with no BCR, was 38% (84/221 men) at 12 months. CONCLUSIONS: Our prospective study of men with very-low-risk prostate cancer undergoing open or robot-assisted radical prostatectomy showed that there were favourable oncological outcomes in approximately two-thirds. Approximately 40% did not have surgically induced urinary incontinence or erectile dysfunction 12 months postoperatively. These results provide additional support for the use of active surveillance in men with very-low-risk prostate cancer; however, the number of men with risk of upgrading and upstaging is not negligible. Improved stratification is still urgently needed.
OBJECTIVES: To analyse oncological and functional outcomes 12 months after treatment of very-low-risk prostate cancer with radical prostatectomy in men who could have been candidates for active surveillance. PATIENTS AND METHODS: We conducted a prospective study of all men with very-low-risk prostate cancer who underwent radical prostatectomy at one of 14 participating centres. Validated patient questionnaires were collected at baseline and after 12 months by independent healthcare researchers. Biochemical recurrence (BCR) was defined as prostate-specific antigen (PSA) ≥0.25 ng/mL or treatment with salvage radiotherapy or with hormones. Urinary continence was defined as <1 pad changed per 24 h. Erectile function was defined as ability to achieve erection hard enough for penetration more than half of the time after sexual stimulation. Changes in tumour grade and stage were obtained from pathology reports. We report descriptive frequencies and proportions of men who had each outcome in various subgroups. Fisher's exact test was used to assess differences between the age groups. RESULTS: Of the 4003 men in the LAPPRO cohort, 338 men fulfilled the preoperative national criteria for very-low-risk prostate cancer. Adverse pathology outcomes included upgrading, defined as pT3 or postoperative Gleason sum ≥7, which was present in 35% of the men (115/333) and positive surgical margins, which were present in 16% of the men (54/329). Only 2.1% of the men (7/329) had a PSA concentration >0.1 ng/mL 6-12 weeks postoperatively. Erectile function and urinary continence were observed in 44% (98/222) and 84% of the men (264/315), respectively, 12 months postoperatively. The proportion of men achieving the trifecta, defined as preoperative potent and continent men who remained potent and continent with no BCR, was 38% (84/221 men) at 12 months. CONCLUSIONS: Our prospective study of men with very-low-risk prostate cancer undergoing open or robot-assisted radical prostatectomy showed that there were favourable oncological outcomes in approximately two-thirds. Approximately 40% did not have surgically induced urinary incontinence or erectile dysfunction 12 months postoperatively. These results provide additional support for the use of active surveillance in men with very-low-risk prostate cancer; however, the number of men with risk of upgrading and upstaging is not negligible. Improved stratification is still urgently needed.
Authors: Vincenzo Ficarra; Giacomo Novara; Thomas E Ahlering; Anthony Costello; James A Eastham; Markus Graefen; Giorgio Guazzoni; Mani Menon; Alexandre Mottrie; Vipul R Patel; Henk Van der Poel; Raymond C Rosen; Ashutosh K Tewari; Timothy G Wilson; Filiberto Zattoni; Francesco Montorsi Journal: Eur Urol Date: 2012-06-01 Impact factor: 20.096
Authors: Albert El Hajj; Guillaume Ploussard; Alexandre de la Taille; Yves Allory; Dimitri Vordos; Andras Hoznek; Claude Clément Abbou; Laurent Salomon Journal: BJU Int Date: 2012-06-21 Impact factor: 5.588
Authors: Quoc-Dien Trinh; Anders Bjartell; Stephen J Freedland; Brent K Hollenbeck; Jim C Hu; Shahrokh F Shariat; Maxine Sun; Andrew J Vickers Journal: Eur Urol Date: 2013-04-19 Impact factor: 20.096
Authors: Vincenzo Ficarra; Giacomo Novara; Raymond C Rosen; Walter Artibani; Peter R Carroll; Anthony Costello; Mani Menon; Francesco Montorsi; Vipul R Patel; Jens-Uwe Stolzenburg; Henk Van der Poel; Timothy G Wilson; Filiberto Zattoni; Alexandre Mottrie Journal: Eur Urol Date: 2012-06-01 Impact factor: 20.096
Authors: Sung Kyu Hong; Itay A Sternberg; Gal E Keren Paz; Philip H Kim; Karim A Touijer; Peter T Scardino; James A Eastham Journal: Eur Urol Date: 2013-08-11 Impact factor: 20.096
Authors: Eva Johansson; Gunnar Steineck; Lars Holmberg; Jan-Erik Johansson; Tommy Nyberg; Mirja Ruutu; Anna Bill-Axelson Journal: Lancet Oncol Date: 2011-08-05 Impact factor: 41.316
Authors: Gail Dunberger; Helena Lind; Gunnar Steineck; Ann-Charlotte Waldenström; Tommy Nyberg; Massoud al-Abany; Ullakarin Nyberg; Elisabeth Avall-Lundqvist Journal: Int J Gynecol Cancer Date: 2010-04 Impact factor: 3.437
Authors: Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Anna Wallerstedt; Stavros I Tyritzis; Thordis Thorsteinsdottir; Stefan Carlsson; Johan Stranne; Ove Gustafsson; Jonas Hugosson; Anders Bjartell; Ulrica Wilderäng; N Peter Wiklund; Gunnar Steineck; Eva Haglind Journal: Eur Urol Date: 2014-10-11 Impact factor: 20.096
Authors: Eugenio Martorana; Giacomo Maria Pirola; Maria Cristina Aisa; Pietro Scialpi; Aldo Di Blasi; Giovanni Saredi; Alfredo D'Andrea; Stefano Signore; Riccardo Grisanti; Michele Scialpi Journal: Turk J Urol Date: 2019-07-01
Authors: Sadhna Verma; Peter L Choyke; Steven C Eberhardt; Aytekin Oto; Clare M Tempany; Baris Turkbey; Andrew B Rosenkrantz Journal: Radiology Date: 2017-11 Impact factor: 11.105
Authors: Badereddin Mohamad Al-Ali; Anton Ponholzer; Herbert Augustin; Stephan Madersbacher; Karl Pummer Journal: Biomed Res Int Date: 2017-02-05 Impact factor: 3.411
Authors: Glen Denmer R Santok; Ali Abdel Raheem; Lawrence Hc Kim; Kidon Chang; Trenton Gh Lum; Byung Ha Chung; Young Deuk Choi; Koon Ho Rha Journal: Investig Clin Urol Date: 2017-02-15
Authors: Dong-Ho Mun; Lin Yang; Shahrokh F Shariat; Sylvia Reitter-Pfoertner; Gerald Gredinger; Thomas Waldhoer Journal: Int J Environ Res Public Health Date: 2021-06-27 Impact factor: 3.390
Authors: Dorota Szczygielska; Andrzej Knapik; Teresa Pop; Jerzy Rottermund; Edward Saulicz Journal: Int J Environ Res Public Health Date: 2022-03-02 Impact factor: 3.390